What is Syncardia Systems?
Headquartered in Tucson, Arizona, Syncardia Systems is the sole manufacturer of the FDA, Health Canada, and CE-approved Total Artificial Heart. The company serves a vital niche in the medical device sector, providing a bridge-to-transplant solution for patients suffering from severe biventricular failure. Beyond the core artificial heart technology, the firm produces the Freedom portable driver, a critical innovation that enables patients to transition from hospital-bound care to home-based recovery while awaiting a donor organ. This dual-product strategy positions Syncardia as a cornerstone of modern cardiac care, effectively extending the survival window for patients with limited therapeutic alternatives.
How much funding has Syncardia Systems raised?
Syncardia Systems has raised a total of $42.3M across 7 funding rounds:
Series B
$3.7M
Series D
$10.3M
Private Equity
$5M
Debt
$14M
Private Equity
$6.4M
Debt
$1M
Debt
$1.9M
Series B (2004): $3.7M, investors not publicly disclosed
Series D (2009): $10.3M led by Highway 12 Ventures
Private Equity (2011): $5M, investors not publicly disclosed
Debt (2013): $14M featuring Athyrium Capital Management and SWK Holdings
Private Equity (2014): $6.4M, investors not publicly disclosed
Debt (2020): $1M with participation from PPP
Debt (2021): $1.9M led by PPP
Key Investors in Syncardia Systems
Athyrium Capital Management
Athyrium Capital Management is a leading investment management platform focused on structured investments in the global healthcare sector, providing financing solutions that support growth objectives.
SWK Holdings
SWK Holdings is a life science specialty finance company that provides innovative capital solutions to a broad range of life science companies, institutions, and inventors.
Highway 12 Ventures
Highway 12 Ventures is a venture capital and private equity firm based in Boise, Idaho, that focuses on supporting high-growth companies within the technology and healthcare sectors.
What's next for Syncardia Systems?
Looking ahead, Syncardia Systems is positioned to leverage its recent capital influx to optimize its supply chain and expand the clinical reach of its portable driver technology. As the company moves beyond its initial development and scaling phases, the focus will likely shift toward enhancing the durability of its mechanical circulatory support systems and exploring new regulatory pathways for broader patient eligibility. The strategic integration of debt and equity financing provides the necessary liquidity to navigate the complex regulatory landscape of the medical device industry, ensuring that the firm remains at the forefront of life-saving cardiovascular interventions. Continued investment in research and development will be paramount as the company seeks to maintain its market leadership in the face of evolving transplant technologies.
See full Syncardia Systems company page
